MRNA Stock: Citi Questions Whether Melanoma Vaccine’s Benefit Justifies Individualized Tumor Harvesting And Manufacturing
MRNA Stock: Citi Questions Whether Melanoma Vaccine’s Benefit Justifies Individualized Tumor Harvesting And Manufacturing TradingView
Covered in this story
What has happened since
- Moderna is up 0.0% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Moderna
- Citi: $193 → $80 by Sep 2027 · Sell via 247wallst.com
- Rothschild & Co Redburn: $149 → $81 by Sep 2027 · Sell via Investing.com
- Morgan Stanley: $174 → $89 by Aug 2027 · Equalweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Moderna →Dalsna Finance is currently tracking 16 stories mentioning Moderna, the earliest published 4 Oct 2026.
Summary aggregated from TradingView's public RSS feed. The full reporting belongs to TradingView — please read it on their site.